Covid, Italian MD’s Plasma Therapy disparaged by Wikipedia but celebrated in US. “It Healed 95thousands Americans”, study
Research on Johns Hopkins Bloomberg School of Public Health
reveals the effectiveness of the therapy of the Italian doctor
who died in a suspected suicide
by Fabio Giuseppe Carlo Carisio
On August,2, in the Basilica of Mantua, to give the last sad farewell to Professor Giuseppe De Donno, there were no national authorities of the great celebrations, perhaps fearful of taking the whistles and insults that rained down during the funeral of Giovanni Falcone and Paolo Borsellino.
But there were many police and Digos men who would have prevented a man, according to local newspapers, from displaying a sign reading “Killed by the State” in the crowded Mantegna square up to the nearby bridges of about 700 people.
De Donno, as is known, was found hanged in his house in the Hermitage of Curtatone, on the outskirts of Mantua. His apparently inexplicable gesture (and which is not explained by any farewell note) has triggered the suspicion of an incitement to suicide, so much so as to induce the Prosecutor of Mantua to open an investigation by seizing PCs and smartphones, and the most extreme one for something worse …
Beyond the different deaths between the world doctor symbol of anti-Covid therapy with hyperimmune plasma and the two magistrates heroes in the fight against the Mafia, their fate appears marked by the common misfortune of having been completely isolated from the Italian state.
The judges because they investigated the affairs among Freemasonry, the mafia, politics and procurement in the Bribery of Palermo (from which the current President of the Italian Republic Sergio Mattarella came out unscathed by a whisker).
De Donno because he was rewriting the fight against Covid-19 according to a narrative that was too uncomfortable for those politicians (the premier Giuseppe Conti and Mario Draghi and the Minister of Health Roberto Speranza, all nominated or recommended by Mattarella himself) who had already joined the plan Big Pharma global health care tracked in the Prophetic Event 201 simulated exercise in October 2019 in New York, funded by the Bill & Melinda Gates Foundation.
As that time, two months before the official discovery of SARS-Cov-2 in Wuhan, action against a Coronavirus pandemic was planned and prepared through a symposium capable of predicting in detail the immediate success of an antiviral (later revealed to be the Remdesivir of the Gilead) and then that of an experimental vaccine (a year later came the Comirnaty of Pfizer controlled by GSK of which Gates himself is a shareholder).
WIKIPEDIA’S SCAR TO PLASMA TREATMENTS
Before the last of a moved crowd and a rash parish priest in the homily as much as Don Abbondio in the Promessi Sposi, trained to callidly avoid any reference to the noble activity of the Pulmonologist as if his wedding with the success of the plasma were not to be celebrated, is the unexpected disfigurement of the Web has come, which erases and rewrites human biographies thanks to “four pilots’ trained in Artificial Intelligence, so that everything is Politically Correct. In fact, on Sunday afternoon, on the eve of De Donno’s funeral, his Wikipedia page disappeared. Fans of him immediately shouted the conspiracy. Wikipedia censors explained that it was being updated … almost complete, then!
It reappeared updated at 12.35 on 2 August, practically at a funeral that ended with an even worse scar. A double quote on the useless therapy with hyperimmune plasma: “In November 2020, a study carried out by the Italian Hospital of Buenos Aires and published in the New England Journal of Medicine had argued that the use of hyperimmune plasma on patients suffering from Covid- 19 had no effect “, reads Wikipedia
«On May 14, 2021, the medical journal The Lancet published the results of the scientific study conducted in 177 public hospitals in the United Kingdom on 11 558 patients to evaluate the effectiveness of the method proposed by De Donno. The conclusion of the study was that “in patients hospitalized with COVID-19, the use of autoimmune plasma (high-titre convalescent plasma) did not improve the survival rate or other pre-specific clinical outbreaks” »continues the well-shrewd Encyclopedia in treating the topics dear to the so-called New World Order.
No reference to the fact that the experimental therapy shared by the Poma hospitals in Mantua and San Matteo di Pavia was destined for another one in Pisa, the case passed to the Parliament which evaluated the offer of collaboration of an Italian company leader in pharmacology on blood products in partnership with an Israeli of a Big Pharma that controls Moderna of which Gates himself became a shareholder. The De Donno project thus vanished into political mysteries …
Too bad, because in spring 2020 Professor Cesare Perotti declared at a conference: «We have collected 329 donations, with donors also coming from Trentino. A manifestation of great generosity, which now allows us to have a number of plasma bags available to use in the event of a possible second wave in the fall. The use of hyperimmune plasma reduced mortality by 15 to 6 percent. Our work was also recognized by the European Commission, which assigned us the task of writing guidelines for the whole of Europe for therapy with plasma donated by convalescent patients “.
DE DONNO: THE REVENGE COMES NOW FROM THE USA
He left the direction of the pneumology department of the Mantua hospital after 8 years. And he began to be a family doctor. He too was a little targeted by the more extreme No Vax because he declared himself in favor of the vaccine, although he really trusted in alternative treatments such as transfusions with the hyperimmune plasma of the recovered patients.
Because of politics, his name was marginalized to that of a doctor against the system. However, this did not prevent his therapy from arriving in the US, being tested by 117 university hospitals, even convincing the actor Tom Hanks to donate blood after his recovery from Covid.
And now that he has died in the rapid oblivion of the Italian scientific community, the most unexpected and surprising celebration reaches Professor Giuseppe. His therapy saved 95,000 Americans! And he could have saved another 29,000 if it had been used with more conviction by US hospitals that were instead distracted by the clinical studies that Wikipedia stands for.
To write it clearly is the Johns Hopkins Bloomberg School of Public Health in Baltimore which last June 7 published a scientific study on the matter on its official website, which was ignored by the mainstream media that fear any alternative to the political strategy of Big Pharma on Vaccines to the bitter end (Israel has already started the administration of the third dose for the nightmare of the Delta Variant, not very lethal but very contagious even for the vaccinated).
Johns Hopkins is not only the university that keeps the world tally of Covid-19 cases but it is also the body that organized the aforementioned Event 201 funded by Gates. Therefore it certainly cannot be accused of anti Vax conspiracy or of boasting credits that are and always will be of Professor Giuseppe De Donno. Pugnacious pulmonologist, to death!
Here is the full text published by the Johns Hopkins Bloomberg School of Public Health translated into Italian.
Drop in Convalescent Plasma Use at U.S. Hospitals
Linked to Higher COVID-19 Mortality Rate
Analysis suggests decline in Convalescent Plasma
use in US hospitals from november 2020 to february 2021
may have led to as many as 29,000 excess covid-19 deaths
First posted on Johns Hopkins Bloomberg School of Public Health
A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter’s surge.
U.S. hospitals began treating COVID-19 patients with convalescent plasma therapy—which uses antibody-rich blood from recovered COVID-19 patients—in the summer of 2020 when doctors were looking to identify treatments for the emerging disease. By the spring of 2021, doctors in the United States had treated over 500,000 COVID-19 patients with convalescent plasma. The use of convalescent plasma started declining late in 2020 after several large clinical trials showed no apparent benefit.
The researchers’ analysis suggests that the decline in convalescent plasma use might have led to more than 29,000 excess COVID-19 deaths from November 2020 to February 2021. The study was published online June 4 in the journal eLife.
“Clinical trials of convalescent plasma use in COVID-19 have had mixed results, but other studies, including this one, have been consistent with the idea that it does reduce mortality,” says study senior author Arturo Casadevall, MD, PhD, Alfred and Jill Sommer Professor and Chair of the Department of the Molecular Microbiology and Immunology at the Bloomberg School.
The study was done in collaboration with researchers at Michigan State University and the Mayo Clinic. Casadevall and colleagues observed that while plasma use was declining late last year, the reported COVID-19 patient mortality rate was rising. That led them to hypothesize that the two phenomena were related.
In the study, the researchers compared the number of units of plasma distributed to U.S. hospitals from blood banks, on a per patient basis, to the number of reported COVID-19 deaths per hospital admission across the country.
One finding was that while the total use of plasma peaked last December and January during the winter surge in new COVID-19 patients, the use per hospitalized patient peaked in early October 2020—just as deaths per COVID-19 hospital admission bottomed. Thereafter, in the wake of reports of negative results from clinical trials, use of plasma per hospitalized patient fell sharply—and deaths per COVID-19 hospital admission rose.
The researchers analyzed the relationship between these two datasets and found a strong negative correlation, higher use rate being associated with lower mortality and vice versa. They also grouped periods of plasma use into five “quintile” groupings from lowest-use weeks to highest, and found a graded relationship between less use and higher mortality.
A model the researchers generated to fit the data suggested that the COVID-19 case fatality rate decreased by 1.8 percentage points for every 10-percentage point increase in the rate of plasma use. That model implied that there would have been 29,018 fewer deaths, from November 2020 to February 2021, if the peak use rate of early October had held. Moreover, it suggested that the use of plasma on the whole, as limited as it was, prevented about 95,000 deaths through early March of this year.
The researchers analyzed, and then rejected, the possibility that several other factors could explain away the link between less plasma use and more mortality. These factors included changes in the average age of hospitalized patients, and the emergence of new variants of the COVID-19-causing coronavirus.
As for why some clinical trials found no benefit for plasma use, the researchers note in their paper that many of the clinical trials with negative results had used plasma—mainly considered an antiviral treatment—relatively late in the course of COVID-19, when patients may have been too ill to benefit, and when the disease is driven mainly by immune-related responses rather than the coronavirus itself.
Casadevall notes that convalescent plasma remains under FDA Emergent Use Authorization in the U.S., and that it is readily available. “We hope that physicians, policymakers, and regulators will consider the totality of the available evidence, including our findings, when making decisions about convalescent plasma use in individual COVID-19 patients,” Casadevall says.
“Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality” was co-authored by Arturo Casadevall, Quigly Dragotakes, Patrick Johnson, Jonathon Senefeld, Stephen Klassen, R. Scott Wright, Michael Joyner, Nigel Paneth, and Rickey Carter.
There was no specific funding for this study. Individual authors have been supported by the National Institutes of Health (RO1 HL059842; R01 AI152078 9; 5R35HL139854).This project has been funded in whole or in part by the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096.